A New Hope for Alzheimer’s Patients: Donanemab and Its Impact on Disease Progression
Alzheimer’s disease remains one of the most challenging neurodegenerative disorders to treat, with its progressive cognitive decline and memory loss affecting millions worldwide. Recently, a new monoclonal antibody targeting amyloid plaques in the brain, donanemab, has been developed and successfu...